Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Launch of Salivary Cortisol Hypertension Assay

18 Dec 2015 09:43

RNS Number : 5543J
Immunodiagnostic Systems Hldgs PLC
18 December 2015
 

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

18 December 2015

 

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS Salivary Cortisol Hypertension Assay

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS Salivary Cortisol assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS Salivary Cortisol assay enhances the IDS Hypertension panel, which also includes the automated IDS-iSYS Aldosterone and IDS-iSYS Direct Renin immunoassays.

The IDS-iSYS Salivary Cortisol assay measures a patient's salivary cortisol and offers clinicians an easy, non-invasive way to diagnose diseases of cortisol imbalance such as Cushing's Syndrome (CS). One sign of CS is a higher than expected level of cortisol, which can often lead to hypertension.

As the fastest salivary cortisol automated test on the market the IDS-iSYS Salivary Cortisol assay allows laboratories to benefit from a reduced time to first result.

The global market size of salivary cortisol testing is estimated to be around £5 - £10 million.

For further information:

Immunodiagnostic Systems Holdings plc Telephone: +44(0)191 519 0660Patricio Lacalle, CEOJaap Stuut, Marketing DirectorPeel Hunt LLP Telephone: +44(0)207 418 8900James Steel

 

About Immunodiagnostic Systems Holdings plc.:A Specialist in Endocrinology TestingImmunodiagnostic Systems Holdings plc (IDS) is a leading in vitro diagnostic solution provider to the clinical laboratory market. IDS develop, manufacture and market innovative immunoassays and automated immunoanalyser technologies to provide improved diagnostic outcomes for patients. The IDS immunoassay portfolio is a combination of an endocrinology specialty testing menu and assay panels in complementary fields.

IDS was founded in 1977 and trades on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.IDS is a global company headquartered in the UK with around 400 employees worldwide. The group's products are developed and manufactured at their facilities in Europe. IDS serve customers through regional offices in Europe, U.S.A. and Brazil. The group's network of distributors work on IDS' behalf to serve customers throughout the rest of the world.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGCBDDDSBBGUI

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.